Stapled peptides as potential therapeutics for diabetes and other metabolic diseases - 08/11/24
, Dominika Rubiak b, Agnieszka J. Pietrzyk-Brzezińska a, Joanna Małolepsza b, Katarzyna M. Błażewska b, ⁎ , Edyta Gendaszewska-Darmach a, ⁎ Abstract |
The field of peptide drug research has experienced notable progress, with stapled peptides featuring stabilized α-helical conformation, emerging as a promising field. These peptides offer enhanced stability, cellular permeability, and binding affinity and exhibit potential in the treatment of diabetes and metabolic disorders. Stapled peptides, through the disruption of protein-protein interactions, present varied functionalities encompassing agonism, antagonism, and dual-agonism. This comprehensive review offers insight into the technology of peptide stapling and targeting of crucial molecular pathways associated with glucose metabolism, insulin secretion, and food intake. Additionally, we address the challenges in developing stapled peptides, including concerns pertaining to structural stability, peptide helicity, isomer mixture, and potential side effects.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Abbreviations : ABCA1, AC, Aib, AID, AKAP, Akt, ALMS-1, ApoA-I, ASC, Atg14L, BAD, Bcl-2, Beclin-1, BH3, BTB/POZ, CCK, CCK-2R, CE, CETP, CH, CRL, Cul, DIO, DPP-4, EGFR, ERK1/2, FBS, FDA, GAP, GCG, GCGR, GDI, GEF, GIP, GIP, GIPR, GK, GLP-1, GLP-1 RA, GLUT4, GPCR, GPR10/PrRPR, HDL, I.c.v, I.p., I.v., IGF-1/2, IGF-1/2 R, IL-1β/18, INSL3, IR, IRS-1/2, ITC, JAK, KCTD, LCAT, LDL, LDLR, MAPK, MD, NEP 24.11, NLRP3, NPY, NPY2R, PACAP, PATAS, PCSK9, PI3K, PI3K, PKA, PKC, PKI, PL, PLC, PPAR, PPI, PrRP, PYD, PYY, Rac1, RING, ROS, RXFP, RXR, S.c., SAHB, SecR, SH2, SOCS, STAD, STAT, T2D, TG, Tiam1, TNF-α, TZD, UVRAG, VGCC, VIP, VPAC2, VPS15
Keywords : Stapled peptides, diabetes, metabolic diseases, antidiabetic molecular targets
Plan
Vol 180
Article 117496- novembre 2024 Retour au numéro
Article précédent
- Unlocking the potential of extracellular vesicle circRNAs in breast cancer: From molecular mechanisms to therapeutic horizons
- Lijuan Fang, Zehua Zhu, Mingyue Han, Shaojie Li, Xiangyi Kong, Lusen Yang
- The Wnt signaling pathway in hepatocellular carcinoma: Regulatory mechanisms and therapeutic prospects
- Shihui Ma, Guorui Meng, Tong Liu, Junqi You, Risheng He, Xudong Zhao, Yunfu Cui
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?